Cerus Corp About
Cerus Corp Cerus is also pursuing other
therapeutic applications to treat and prevent serious diseases. Current studies
are evaluating the use of Helinx to improve the outcome of stem
cell transplanation procedures and to protect immunocompromised organ transplant
patients against Epstein Barr virus (EBV) infection. Read
more on The Intercept Blood System for Platelets and Plasma More
on Cerus Corp
Cerus Corporation (Nasdaq: CERS), has a platform technology (Helinx®) that
prevents nucleic acid (DNA and RNA) replication. The Company's initial application
of this technology is the development of the INTERCEPT Blood System to inactivate
viruses, bacteria and other pathogens in the blood components used for transfusion
- platelets,
plasma and red blood cells.